3/21/2023 7:40:48 AM
Enveric Biosciences Establishes Enveric Therapeutics To Support The Company's Plans To Advance EVM201 Series
2/28/2023 7:36:18 AM
Enveric Biosciences Names Kevin Coveney CFO, Effective March 13
11/28/2022 7:36:22 AM
Enveric Biosciences Submits Registration Statement For Spin-off Of Its Cannabinoid Business To Shareholders
10/24/2022 7:08:53 AM
Enveric Biosciences Advances Lead Candidate For Anxiety Disorders To IND-Enabling Studies
7/25/2022 8:10:29 AM
Enveric Biosciences Announces $8 Mln Registered Direct Offering And Private Placement
7/13/2022 7:32:39 AM
Enveric Biosciences Advances Drug Development For Mental Health Indications And Intellectual Property Portfolio
5/11/2022 7:32:12 AM
Enveric Biosciences Plans To Spin-off And Dividend Cannabinoid Pipeline
3/15/2022 7:33:01 AM
Enveric Announces Publication Of Four Patent Applications For Psychedelic-Inspired Drug Candidates
12/6/2021 7:32:12 AM
Enveric Biosciences Appoints Bob Dagher As Chief Medical Officer
10/5/2021 7:38:52 AM
Enveric Biosciences : PsyAI Identifies Viable Drug Candidates From 'Psybrary' Of Psychedelic Molecular Compounds
9/17/2021 7:09:58 AM
Enveric Biosciences Announces Closing Of MagicMed Industries Acquisition
7/8/2021 8:09:24 AM
Enveric Biosciences : Israel Approves To Begin Phase 1/2 Trial Of Triple-Combination CBD Treatment For Glioblastoma
5/24/2021 6:01:52 AM
Enveric Biosciences Agrees To Acquire MagicMed Industries